NICE IDs

01/04/2026

ID6407: Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over

31/03/2026

ID6496: Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881)

25/03/2026

ID6441: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

06/03/2026

ID6477: Pembrolizumab before surgery (neoadjuvant) then with radiotherapy after surgery (adjuvant) for newly diagnosed, resectable, locally advanced, squamous cell head and neck cancer

04/03/2026

ID5071: Fezolinetant for treating vasomotor symptoms associated with the menopause

02/03/2026

ID6474: Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment

02/02/2026

ID6168: Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer

30/01/2026

ID6480: Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648)

26/01/2026

ID6403: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673)

22/01/2026

ID6420: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

22/01/2026

ID6485: Targeted-release budesonide for treating primary IgA nephropathy (review of TA937)

20/01/2026

ID6235: Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

20/01/2026

ID6310: Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer

02/01/2026

ID6369: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

23/12/2025

ID6369: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

23/12/2025

ID6369: Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy

16/12/2025

ID6211: Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma

16/12/2025

ID6291: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable

15/12/2025

ID4004: Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer

15/12/2025

ID6256: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer